137 related articles for article (PubMed ID: 15766244)
1. Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.
Arimondo PB; Laco GS; Thomas CJ; Halby L; Pez D; Schmitt P; Boutorine A; Garestier T; Pommier Y; Hecht SM; Sun JS; Bailly C
Biochemistry; 2005 Mar; 44(11):4171-80. PubMed ID: 15766244
[TBL] [Abstract][Full Text] [Related]
2. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
4. Triple helix-forming oligonucleotides conjugated to new inhibitors of topoisomerase II: synthesis and binding properties.
Duca M; Oussedik K; Ceccaldi A; Halby L; Guianvarc'h D; Dauzonne D; Monneret C; Sun JS; Arimondo PB
Bioconjug Chem; 2005; 16(4):873-84. PubMed ID: 16029029
[TBL] [Abstract][Full Text] [Related]
5. Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.
Arimondo PB; Thomas CJ; Oussedik K; Baldeyrou B; Mahieu C; Halby L; Guianvarc'h D; Lansiaux A; Hecht SM; Bailly C; Giovannangeli C
Mol Cell Biol; 2006 Jan; 26(1):324-33. PubMed ID: 16354702
[TBL] [Abstract][Full Text] [Related]
6. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification.
Wang X; Wang LK; Kingsbury WD; Johnson RK; Hecht SM
Biochemistry; 1998 Jun; 37(26):9399-408. PubMed ID: 9649322
[TBL] [Abstract][Full Text] [Related]
8. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides.
Hélène C
Anticancer Drug Des; 1991 Dec; 6(6):569-84. PubMed ID: 1772570
[TBL] [Abstract][Full Text] [Related]
9. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
10. Triple helix formation by (G,A)-containing oligonucleotides: asymmetric sequence effect.
Arimondo PB; Barcelo F; Sun JS; Maurizot JC; Garestier T; Hélène C
Biochemistry; 1998 Nov; 37(47):16627-35. PubMed ID: 9843430
[TBL] [Abstract][Full Text] [Related]
11. Effects of camptothecin analogues on DNA transformations mediated by calf thymus and human DNA topoisomerases I.
Wang X; Short GF; Kingsbury WD; Johnson RK; Hecht SM
Chem Res Toxicol; 1998 Nov; 11(11):1352-60. PubMed ID: 9815197
[TBL] [Abstract][Full Text] [Related]
12. Raman and CD spectroscopy of recombinant 68-kDa DNA human topoisomerase I and its complex with suicide DNA-substrate.
Fleury F; Ianoul A; Kryukov E; Sukhanova A; Kudelina I; Wynne-Jones A; Bronstein IB; Maizieres M; Berjot M; Dodson GG; Wilkinson AJ; Holden JA; Feofanov AV; Alix AJ; Jardillier JC; Nabiev I
Biochemistry; 1998 Oct; 37(41):14630-42. PubMed ID: 9772192
[TBL] [Abstract][Full Text] [Related]
13. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex.
Wang X; Zhou X; Hecht SM
Biochemistry; 1999 Apr; 38(14):4374-81. PubMed ID: 10194356
[TBL] [Abstract][Full Text] [Related]
14. Design and optimization of camptothecin conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage by topoisomerase I.
Arimondo PB; Boutorine A; Baldeyrou B; Bailly C; Kuwahara M; Hecht SM; Sun JS; Garestier T; Hélène C
J Biol Chem; 2002 Feb; 277(5):3132-40. PubMed ID: 11724801
[TBL] [Abstract][Full Text] [Related]
15. Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.
Arimondo PB; Angenault S; Halby L; Boutorine A; Schmidt F; Monneret C; Garestier T; Sun JS; Bailly C; Hélène C
Nucleic Acids Res; 2003 Jul; 31(14):4031-40. PubMed ID: 12853620
[TBL] [Abstract][Full Text] [Related]
16. Stem-loop oligonucleotides as tools for labelling double-stranded DNA.
Géron-Landre B; Roulon T; Escudé C
FEBS J; 2005 Oct; 272(20):5343-52. PubMed ID: 16218964
[TBL] [Abstract][Full Text] [Related]
17. Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target.
Capobianco ML; De Champdoré M; Arcamone F; Garbesi A; Guianvarc'h D; B Arimondo P
Bioorg Med Chem; 2005 May; 13(9):3209-18. PubMed ID: 15809156
[TBL] [Abstract][Full Text] [Related]
18. The development of bioactive triple helix-forming oligonucleotides.
Seidman MM; Puri N; Majumdar A; Cuenoud B; Miller PS; Alam R
Ann N Y Acad Sci; 2005 Nov; 1058():119-27. PubMed ID: 16394131
[TBL] [Abstract][Full Text] [Related]
19. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage.
Holden JA; Wall ME; Wani MC; Manikumar G
Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides.
Duca M; Guianvarc'h D; Oussedik K; Halby L; Garbesi A; Dauzonne D; Monneret C; Osheroff N; Giovannangeli C; Arimondo PB
Nucleic Acids Res; 2006; 34(6):1900-11. PubMed ID: 16598074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
